These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 8695345)

  • 81. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The clinical pharmacology of topoisomerase I inhibitors.
    Abang AM
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Role of topoisomerase I inhibitors in small-cell lung cancer.
    Fukuoka M
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Irinotecan in small-cell lung cancer: the US experience.
    Sandler AB
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):11-2. PubMed ID: 11221015
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The current status of irinotecan (CPT-11) in the United States.
    Rothenberg ML
    Ann N Y Acad Sci; 1996 Dec; 803():272-81. PubMed ID: 8993521
    [No Abstract]   [Full Text] [Related]  

  • 90. CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.
    Bleiberg H
    Tumori; 1997; 83(1 Suppl):S85-6. PubMed ID: 9154078
    [No Abstract]   [Full Text] [Related]  

  • 91. Experience with irinotecan for the treatment of malignant glioma.
    Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS
    Neuro Oncol; 2009 Feb; 11(1):80-91. PubMed ID: 18784279
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.
    Arun B; Frenkel EP
    Expert Opin Pharmacother; 2001 Mar; 2(3):491-505. PubMed ID: 11336601
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Treatment of central nervous system xenografts with camptothecins.
    Friedman HS; Houghton PJ
    Ann N Y Acad Sci; 1996 Dec; 803():210-2. PubMed ID: 8993514
    [No Abstract]   [Full Text] [Related]  

  • 94. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
    Lamond JP; Mehta MP; Boothman DA
    J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The clinical development of 9-aminocamptothecin.
    Takimoto CH; Thomas R
    Ann N Y Acad Sci; 2000; 922():224-36. PubMed ID: 11193898
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Toxicity of the topoisomerase I inhibitors.
    Seiter K
    Expert Opin Drug Saf; 2005 Jan; 4(1):45-53. PubMed ID: 15709897
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinical studies of camptothecin and derivatives.
    Soepenberg O; Sparreboom A; Verweij J
    Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
    [No Abstract]   [Full Text] [Related]  

  • 98. Future directions for clinical research with CPT-11 (irinotecan).
    von Hoff D
    Eur J Cancer; 1996; 32A Suppl 3():S9-12. PubMed ID: 8943659
    [TBL] [Abstract][Full Text] [Related]  

  • 99. New natural products in cancer chemotherapy.
    Slichenmyer WJ; Von Hoff DD
    J Clin Pharmacol; 1990 Sep; 30(9):770-88. PubMed ID: 1980498
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Topoisomerase I interactive drugs in children with cancer.
    Stewart CF; Zamboni WC; Crom WR; Gajjar A; Heideman RL; Furman WL; Meyer WH; Houghton PJ; Pratt CB
    Invest New Drugs; 1996; 14(1):37-47. PubMed ID: 8880392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.